Rezolute Investor Deck: $5B+ TAM, $108M Cash, upLIFT Data Mid-December
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute's new investor presentation quantifies a $5B+ global opportunity across congenital and tumor hyperinsulinism, confirms $108M cash with runway to Q1 2028, and sets tumor HI upLIFT topline for mid-December 2026.
Key Events · Product Development and Regulatory · RZLT
-
Investor Deck Quantifies $5B+ Market
Management sized congenital HI at ~2,000 addressable US patients and $750M-$1B TAM, and tumor HI at ~4,000 patients and $4-5B TAM, for a combined US opportunity of ~6,000 patients and a global market above $5B.
-
Cash Runway Through Q1 2028
The presentation states $108 million in cash with runway through Q1 2028, covering the December 2026 upLIFT readout but not a full congenital HI launch.
-
upLIFT Topline Due Mid-December 2026
Tumor HI Phase 3 topline is guided to mid-December 2026; the interim read showed 7 of the first 8 participants met the primary endpoint and discontinued IV glucose, with the eighth counted as a non-responder.
-
Congenital HI BLA Targeted for 2027
Following the FDA-recommended Type B pre-BLA meeting, the company targets a congenital HI BLA filing in 2027; the sunRIZE primary SMBG endpoint missed while CGM secondary endpoints were not statistically significant at the pre-specified Week 24 window.
Analysis · RZLT · Life Sciences
For the first time, the deck puts hard numbers on the commercial case for ersodetug: roughly 2,000 addressable congenital HI patients worth $750M-$1B and about 4,000 tumor HI patients worth $4-5B, for a combined US opportunity near 6,000 patients and a global market above $5B. It also anchors the near-term calendar against $108 million of cash that management says funds operations through Q1 2028 — tumor HI upLIFT topline in mid-December 2026 and a congenital HI BLA filing in 2027. That runway covers the upLIFT readout but leaves the congenital HI BLA and any launch dependent on the December data and subsequent financing. The clinical picture is unchanged from what was already disclosed: the sunRIZE primary SMBG endpoint missed on functional unblinding, with CGM secondary endpoints showing reductions that were not statistically significant at the pre-specified Week 24 window.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.7% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RZLT was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $398.5M. The 52-week trading range was $1.07 to $11.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.